A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis
- PMID: 15331566
- DOI: 10.2337/diabetes.53.9.2492
A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis
Abstract
Peptide hormones exert unique actions via specific G protein-coupled receptors; however, the therapeutic potential of regulatory peptides is frequently compromised by rapid enzymatic inactivation and clearance from the circulation. In contrast, recombinant or covalent coupling of smaller peptides to serum albumin represents an emerging strategy for extending the circulating t(1/2) of the target peptide. However, whether larger peptide-albumin derivatives will exhibit the full spectrum of biological activities encompassed by the native peptide remains to be demonstrated. We report that Albugon, a human glucagon-like peptide (GLP)-1-albumin recombinant protein, activates GLP-1 receptor (GLP-1R)-dependent cAMP formation in BHK-GLP-1R cells, albeit with a reduced half-maximal concentration (EC(50)) (0.2 vs. 20 nmol/l) relative to the GLP-1R agonist exendin-4. Albugon decreased glycemic excursion and stimulated insulin secretion in wild-type but not GLP-1R(-/-) mice and reduced food intake after both intracerebroventricular and intraperitoneal administration. Moreover, intraperitoneal injection of Albugon inhibited gastric emptying and activated c-FOS expression in the area postrema, the nucleus of the solitary tract, the central nucleus of the amygdala, the parabrachial, and the paraventricular nuclei. These findings illustrate that peripheral administration of a larger peptide-albumin recombinant protein mimics GLP-1R-dependent activation of central and peripheral pathways regulating energy intake and glucose homeostasis in vivo.
Similar articles
-
Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.Gastroenterology. 2004 Aug;127(2):546-58. doi: 10.1053/j.gastro.2004.04.063. Gastroenterology. 2004. PMID: 15300587
-
An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.Gastroenterology. 2008 Apr;134(4):1137-47. doi: 10.1053/j.gastro.2008.01.017. Epub 2008 Jan 11. Gastroenterology. 2008. PMID: 18313669
-
The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.Endocrinology. 2008 Nov;149(11):5670-8. doi: 10.1210/en.2008-0336. Epub 2008 Jul 31. Endocrinology. 2008. PMID: 18669601
-
Is glucagon-like peptide 1 an incretin hormone?Diabetologia. 1999 Mar;42(3):373-9. doi: 10.1007/s001250051165. Diabetologia. 1999. PMID: 10096792 Review.
-
GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.Regul Pept. 2005 Jun 15;128(2):125-34. doi: 10.1016/j.regpep.2004.07.019. Regul Pept. 2005. PMID: 15780432 Review.
Cited by
-
Cathepsin B Processing Is Required for the In Vivo Efficacy of Albumin-Drug Conjugates.Bioconjug Chem. 2024 Feb 21;35(2):132-139. doi: 10.1021/acs.bioconjchem.3c00478. Epub 2024 Feb 12. Bioconjug Chem. 2024. PMID: 38345213 Free PMC article.
-
Designing and computational analyzing of chimeric long-lasting GLP-1 receptor agonists for type 2 diabetes.Sci Rep. 2023 Oct 18;13(1):17778. doi: 10.1038/s41598-023-45185-1. Sci Rep. 2023. PMID: 37853095 Free PMC article.
-
Incretins-Based Therapies and Their Cardiovascular Effects: New Game-Changers for the Management of Patients with Diabetes and Cardiovascular Disease.Pharmaceutics. 2023 Jul 1;15(7):1858. doi: 10.3390/pharmaceutics15071858. Pharmaceutics. 2023. PMID: 37514043 Free PMC article. Review.
-
Molecular glues modulate protein functions by inducing protein aggregation: A promising therapeutic strategy of small molecules for disease treatment.Acta Pharm Sin B. 2022 Sep;12(9):3548-3566. doi: 10.1016/j.apsb.2022.03.019. Epub 2022 Mar 31. Acta Pharm Sin B. 2022. PMID: 36176907 Free PMC article. Review.
-
Signaling pathways in obesity: mechanisms and therapeutic interventions.Signal Transduct Target Ther. 2022 Aug 28;7(1):298. doi: 10.1038/s41392-022-01149-x. Signal Transduct Target Ther. 2022. PMID: 36031641 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases